ÂÜÀòÂÒÂ×

Dr. Aaron Feng Chen brings to Accutar Biotech nearly 15 years of experience in consulting, biotech, and pharma. Aaron has held increasing responsibilities in a variety of research, strategy, and commercial roles (including strategic planning, market access, marketing, and sales operation). He joined Accutar Biotech from Bayer (2010–2020), where he worked most recently as Senior Director of Global Business Development and Licensing, leading early licensing efforts in oncology. He was part of the Bayer teams establishing and/or executing the Loxo partnership on Vitrakvi® (larotrectinib), the Janssen partnership on Xarelto® (rivaroxaban), and other important licensing and clinical collaboration deals. He also worked as a strategy consultant at McKinsey & Company (2008–2010), and a research analyst at Beijing Genomics Institute (2001–2003). Aaron obtained his Master of Science degree in biochemistry and Doctorate degree in computational biology from the University of Pennsylvania. He has published over 10 articles in top peer-reviewed journals, including Science and Nature Reviews Drug Discovery, with over 3000 citations.